Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

A program for treating olanzapine-related weight gain.

M P Ball1, V B Coons, R W Buchanan

  • 1Maryland Psychiatric Research Center at the University of Maryland School of Medicine, Baltimore 21228, USA. pball@mprc.umaryland.edu

Psychiatric Services (Washington, D.C.)
|July 4, 2001
PubMed
Summary

The Weight Watchers program led to significant weight loss in men with schizophrenia experiencing olanzapine-induced weight gain. No correlation was found between weight loss and psychiatric symptom severity or exercise.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Oxytocin and sexual function in males and females with schizophrenia.

Schizophrenia research·2018
Same author

The use of absorbable gauze (oxidized cellulose) in urological surgery.

The Journal of urology·2010
Same author

Remission in schizophrenia: the relationship to baseline symptoms and changes in symptom domains during a one-year study.

Journal of psychopharmacology (Oxford, England)·2008
Same author

A five-year followup study of deficit and nondeficit schizophrenia.

Schizophrenia research·2001
Same author

Effects of sustained-release bupropion and supportive group therapy on cigarette consumption in patients with schizophrenia.

The American journal of psychiatry·2001
Same author

A separate disease within the syndrome of schizophrenia.

Archives of general psychiatry·2001

Area of Science:

  • Psychiatry
  • Metabolic Disorders
  • Weight Management

Background:

  • Olanzapine, an antipsychotic medication, frequently causes significant weight gain in patients with schizophrenia.
  • Obesity is a common comorbidity in patients with schizophrenia, increasing risks for cardiovascular and metabolic diseases.
  • Effective weight management strategies are crucial for improving the physical health of patients with schizophrenia.

Purpose of the Study:

  • To evaluate the effectiveness of the Weight Watchers program in managing olanzapine-related weight gain in patients with schizophrenia.
  • To determine if psychiatric symptom severity correlates with weight loss success in this patient population.

Main Methods:

  • A cohort of patients with schizophrenia experiencing olanzapine-induced weight gain (≥7% body weight increase) participated in Weight Watchers meetings and supervised exercise.

Related Experiment Videos

  • Weight, body mass index, and psychiatric symptoms were assessed.
  • A matched comparison group not attending the program was used for comparison.

    • Main Results:

    • Significant weight loss was observed exclusively in male participants.
    • No statistically significant weight loss was found in female participants.
    • No correlation was identified between the degree of weight loss and exercise participation or changes in psychiatric symptom severity.

    Conclusions:

    • The Weight Watchers program may be effective for weight reduction in men with schizophrenia experiencing olanzapine-induced weight gain.
    • Weight loss success in this context does not appear to be associated with exercise or changes in psychiatric symptoms.
    • Further research is needed to explore gender-specific responses and optimize weight management interventions for patients with schizophrenia.